Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis

Laboratory Investigation

Volumn 83, Issue 1, 2003, Pages 13-21

  Van Tits, Lambertus ^a   De Graaf, Jacqueline ^a   Hak Lemmers, Heidi ^a   Bredie, Sebastian ^a   Demacker, Pierre ^a   Holvoet, Paul ^b   Stalenhoef, Anton ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ANTIBODY DETECTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPOPROTEIN METABOLISM; MALE; OXIDATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 0037242950     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000048633.76607.E0     Document Type: Article

References (68)

1. Attman PO, Samuelsson O, and Alaupovic P (1993). Lipoprotein metabolism and renal failure. Am J Kidney Dis 21:573-592.
2. Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, and Nube MJ (1997). Low polymorphonuclear cell degranulation during citrate anticoagulation: A comparison between citrate and heparin dialysis. Nephrol Dial Transplant 12:1387-1393.
3. Cases A, Reverter JC, Escolar G, Sanz C, Lopez-Pedret J, Revert L, and Ordinas A (1993). Platelet activation on hemodialysis: Influence of dialysis membranes. Kidney Int Suppl 41:S217-S220.
4. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, and Sawamura T (2000). Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 275:12633-12638.
5. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, and Sawamura T (2001). The binding of oxidized low density lipoprotein (oxLDL) to oxLDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 276:13750-13755.
6. Conti M, Morand PC, Levillain P, and Lemonnier A (1991). Improved fluorometric determination of malonaldehyde. Clin Chem 37:1273-1275.
7. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, and Patrono C (1997). In vivo formation of 8-epi-prostaglandin F2 alpha in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:3230-3235.
8. De Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, and Stalenhoef AF (1991). Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298-306.
9. Demacker PN, Hessels M, Toenhake-Dijkstra H, and Baadenhuijsen H (1997). Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample-to-reagent ratio. Clin Chem 43:663-668.
10. Demacker PN, Sommeren-Zondag DF, Stalenhoef AF, Stuyt PM, and van't Laar A (1983). Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3. Clin Chem 29:656-663.
11. Demuth K, Myara I, Chappey B, Vedie B, Pech-Amsellem MA, Haberland ME, and Moatti N (1996). A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 16:773-783.
12. Devaraj S and Jialal I (1997). Laboratory assessment of lipoprotein oxidation. In: Rifai N, Warnick GRA, and Dominiczak M, editors. Handbook of lipoprotein testing. Washington, DC: AACC Press, 357-373.
13. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, and Becker AE (2001). Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955-1960.
14. Esterbauer H, Striegl G, Puhl H, and Rotheneder M (1989). Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6:67-75.
15. Foley RN and Parfrey PS (1998). Cardiovascular disease and mortality in ESRD. J Nephrol 11:239-245.
16. Foley RN, Parfrey PS, and Sarnak MJ (1998). Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119.
17. Friedewald WT, Levy RI, and Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502.
18. Goldstein JL, Hobbs HH, and Brown MS (1995). Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, and Valle D, editors. The metabolic basis of inherited disease. London: Macmillan magazines, 1981-2030.
19. Haberland ME, Fogelman AM, and Edwards PA (1982). Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci USA 79:1712-1716.
20. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, and Blumberg JB (2001). Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59:1960-1966.
21. Haraki T, Takegoshi T, Kitoh C, Kajinami K, Wakasugi T, Hirai J, Shimada T, Kawashiri M, Inazu A, Koizumi J, and Mabuchi H (2001). Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. Clin Nephrol 56:132-139.
22. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, and Collen D (1996). Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76:663-669.
23. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, and Van de WF (2001). Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848.
24. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, and Collen D (1995). Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95:2611-2619.
25. Holvoet P, Stassen JM, Van Cleemput J, Collen D, and Vanhaecke J (1998a). Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 18:100-107.
26. Holvoet P, Vanhaecke J, Janssens S, Van de Werf, and Collen D (1998b). Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-1494.
27. Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, and Wiklund O (1998). Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 18:1203-1211.
28. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, and Jialal I (2000). Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 150:217-224.
29. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, and Takano T (1996). Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37:45-53.
30. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, and Young IS (1995). Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 41:1135-1138.
31. Kleinveld HA, Hak-Lemmers HL, Stalenhoef AF, and Demacker PN (1992). Improved measurement of low-density lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin Chem 38:2066-2072.
32. Kleinveld HA, Naber AHJ, Stalenhoef AFH, and Demacker PNM (1993). Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: Studies in vitamin E deficient subjects. Free Radic Biol Med 15:273-280.
33. Kotze MJ, Davis HJ, Bissbort S, Langenhoven E, Brusnicky J, and Oosthuizen CJ (1993). Intrafamilial variability in the clinical expression of familial hypercholesterolemia: Importance of risk factor determination for genetic counselling. Clin Genet 43:295-299.
34. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, and Kita T (1998). Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 83:322-327.
35. Lavrencic A, Kosmina B, Keber I, Videcnik V, and Keber D (1996). Carotid intima-media thickness in young patients with familial hypercholesterolaemia. Heart 76:321-325.
36. Li D and Mehta JL (2000a). Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101:2889-2895.
37. Li D and Mehta JL (2000b). Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: Evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 20:1116-1122.
38. Lindner A, Charra B, Sherrard DJ, and Scribner BH (1974). Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697-701.
39. Locatelli F, Del Vecchio L, and Manzoni C (1998). Morbidity and mortality on maintenance haemodialysis. Contrib Nephrol 124:166-189.
40. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, and Trimble ER (1994a). Oxidative stress in haemodialysis. QJM 87:679-683.
41. Loughrey CM, Young IS, McEneny J, McDowell IF, McMaster C, McNamee PT, and Trimble ER (1994b). Oxidation of low density lipoprotein in patients on regular haemodialysis. Atherosclerosis 110:185-193.
42. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
43. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, and Bellomo G (1994a). Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45:876-883.
44. Maggi E, Bellazzi R, Gazo A, Seccia M, and Bellomo G (1994b). Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 46:869-876.
45. Moriwaki H, Kume N, Sawamura T, Aoyama T, Hoshikawa H, Ochi H, Nishi E, Masaki T, and Kita T (1998). Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 18:1541-1547.
46. Morrow JD (2000). The isoprostanes: Their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32:377-385.
47. Myant NB (1983). The metabolic basis of familial hypercholesterolemia. Klin Wochenschr 61:383-401.
48. Nourooz-Zadeh J, Smith CC, and Betteridge DJ (2001). Measures of oxidative stress in heterozygous familial hypercholesterolaemia, Atherosclerosis 156:435-441.
49. O'Byrne D, Devaraj S, Islam KN, Collazo R, McDonald L, Grundy S, and Jialal I (2001). Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism 50:207-215.
50. Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, and London GM (2000). Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 57:1091-1099.
51. Panzetta O, Cominacini L, Garbin U, Fratta PA, Gammaro L, Bianco F, Davoli A, Campagnola M, De Santis A, Pastorino AM, et al (1995). Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: Effects of fish oil and vitamin E administration. Clin Nephrol 44:303-309.
52. Ross R (1986). The pathogenesis of atherosclerosis: An update, N Engl J Med 314:488-500,
53. Ross R (1993). The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809.
54. Sanchez-Quesada JL, Otal-Entraigas C, Franco M, Jorba O, Gonzalez-Sastre F, Blanco-Vaca F, and Ordonez-Llanos J (1999). Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 84:655-659.
55. Savage T, Clarke AL, Giles M, Tomson CR, and Raine AE (1998). Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant 13:2004-2012.
56. Sawamura T and Inoue K (2001). Accelerated atherogenesis in mice overexpressing LOX-1. Circulation 104(Suppl 11):272.
57. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, and Masaki T (1997). An endothelial receptor for oxidized low-density lipoprotein, Nature 386:73-77.
58. Sevanian A, Hwang J, Hodis H, Cazzolato G, Avogaro P, and Bittolo-Bon G (1996). Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 16:784-793.
59. Simon Broome Register Group (1991). Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 303:893-896.
60. Slack J (1969). Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2:1380-1382.
61. Smilde TJ, van den Berkmortel FW, Boers GH, Wollersheim H, de Boo T, van Langen H, and Stalenhoef AF (1998). Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 18:1958-1963.
62. Steinberg D and Lewis A (1997). Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 95:1062-1071.
63. Thompson GR, Seed M, Niththyananthan S, McCarthy S, and Thorogood M (1989). Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 9:175-180.
64. Tonstad S, Joakimsen O, Stensland-Bugge E, Ose L, Bonaa KH, and Leren TP (1998). Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. Eur J Clin Invest 28:971-979.
65. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, and Nagai R (2000). Circulating oxidized low density lipoprotein levels: A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243-2247.
66. Van den Akker JM, Bredie SJH, Diepenveen SHA, Van Tits LJH, Stalenhoef AFH, and Van Leusen R (In press, 2003). Atorvastatin and simvastatin in patients on hemodialysis: Effects on lipoproteins, c-reactive protein and in vivo oxidized LDL. J Nephrol.
67. van Tits LJ, de Waart F, Hak-Lemmers HL, van Heijst P, de Graaf J, Demacker PN, and Stalenhoef AF (2001). Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radic Biol Med 30:1122-1129.
68. Witztum JL and Steinberg D (1991). Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792.